Overall cohort | Moxifloxacin monotherapy | Moxifloxacin combination therapy | Other antibiotic therapy | P-value | |
---|---|---|---|---|---|
Total number (%) | 169 (100) | 42 (25) | 44 (26) | 83 (49) | |
Survivors 30-days (%) | 117 (69) | 28 (67) | 31 (70) | 58 (70) | 0.915 |
Non-Survivors 30-days (%) | 52 (31) | 14 (33) | 13 (30) | 25 (30) | |
Characteristics | |||||
Age yrs. (range/± SD) | 43 (18–75) | 45 (±13.1) | 41 (±12.5) | 43 (±14.7) | 0.473 |
Male gender (%) | 98 (58) | 31 (74) | 25 (57) | 42 (51) | 0.045 |
Female gender (%) | 71 (42) | 11 (26) | 19 (43) | 41 (49) | |
BMI kg/m2 (±SD) | 27,65 (±7.3) | 30,0 (±8.6) | 27,7 (±6.3) | 26,4 (±6.7) | 0.016 |
ECMO-Therapy (%) | 51 (30) | 19 (45) | 13 (30) | 19 (23) | 0.070 |
Dialysis (%) | 83 (49) | 25 (59) | 22 (50) | 36 (43) | 0.337 |
Antibiotics before ICU admission (%) | 142 (84) | 35 (83) | 38 (86) | 69 (83) | 0.885 |
Cardiovascular disease (%) | 25 (14) | 4 (10) | 6 (14) | 15 (14) | 0.432 |
Prior lung disease (%) | 20 (12) | 4 (10) | 7 (16) | 9(18) | 0.609 |
SAPS II (±SD) | 46 (±19.5) | 47 (±19.2) | 40 (±17.7) | 49 (±19.5) | 0.057 |
LIS (±SD) | 3,2 (±0.56) | 3,1 (±0.54) | 3,1 (±0.59) | 3,3 (±0.56) | 0.187 |
SOFA (±SD) | 13 (±6.7) | 15 (±7.3) | 13 (± 5.6) | 12 (±4.4) | 0.131 |
Horowitz-index upon ICU admission (±SD) | 152 (±115.7) | 135 (±99.5) | 221 (±153.0) | 124 (±80.4) | 0.001 |